(Q53305566)

13 May 2018

title

Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. (English)

1 reference

13 May 2018

0 references

A De Nayer

1

1 reference

13 May 2018

E Windhager

2

1 reference

13 May 2018

Irmansyah

3

1 reference

13 May 2018

I Larmo

4

1 reference

13 May 2018

B Lindenbauer

5

1 reference

13 May 2018

H Rittmannsberger

6

1 reference

13 May 2018

T Platz

7

1 reference

13 May 2018

Am Jones

8

1 reference

13 May 2018

Jl Whiteford

9

1 reference

13 May 2018

Ca Altman

10

1 reference

13 May 2018

publication date

1 January 2003

1 reference

13 May 2018

International Journal of Psychiatry in Clinical Practice

published in

1 reference

13 May 2018

volume

7

1 reference

13 May 2018

issue

1

1 reference

13 May 2018

page(s)

59-66

1 reference

13 May 2018

Progress defined--short-term efficacy, long-term effectiveness

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Tolerability of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Extrapyramidal side effects are unacceptable

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Switching antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Dosing and switching strategies for quetiapine fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Review of quetiapine and its clinical applications in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

New atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500310001095

10.1080/13651500310001095

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018